Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.

Cities now have a new tool to more fully understand how the various pieces of the mobility ecosystem are serving the region, and that innovation is also allowing those transportation providers to ...